Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights

Renwei Huang; Yuhe Yin; Zewen Zhao; Xiaoying Dong; Chao Chen; Haowen Lin; Yiming Tao; Siqi Peng; Sichun Wen; Bohou Li; Qiong Wu; Sijia Li; Ting Lin; Hao Dai; Feng Wen; Zhuo Li; Lixia Xu; Jianchao Ma; Shuangxin Liu; Zhonglin Feng

doi:10.12659/AJCR.946727

23 April 2025 : Case report China

Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights

Unusual or unexpected effect of treatment

Renwei Huang

^1EF, Yuhe Yin^1EF, Zewen Zhao^1EF, Xiaoying Dong^1BC, Chao Chen^2B, Haowen Lin^13BC, Yiming Tao^1BC, Siqi Peng^1BC, Sichun Wen^1BC, Bohou Li^1BC, Qiong Wu^1D, Sijia Li^1D, Ting Lin^1D, Hao Dai^1D, Feng Wen^1D, Zhuo Li^1D, Lixia Xu^1D, Jianchao Ma^1D*, Shuangxin Liu^1AG, Zhonglin Feng^1A

DOI: 10.12659/AJCR.946727

Am J Case Rep 2025; 26:e946727

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 2. Changes during drug treatment and clinical indicators. (A) The patient was treated with medication. (B) After the treatment, the patient showed reduced ACR and PCR results. His albumin level increased and serum creatinine was stable. (C) The patient’s PLA2Rab level decreased and IgG level increased. (D) Changes in white blood cell, lymphocyte, and neutrophil counts were observed during the therapy period. PCR – protein-to-creatinine ratio; ACR – albumin-to-creatinine ration; ALB – albumin; Scr – serum creatinine; PLA2Rab – phospholipase A2 receptor antibody; IgG – immunoglobulin G; WBC – white blood cell; NEUT – neutrophil; LYMPH – lymphocyte.

Back to the Article

Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights

Your Privacy